Unknown

Dataset Information

0

Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies.


ABSTRACT: To investigate whether the depletion of nerve growth factor (NGF) is associated with the development of chemotherapy-induced peripheral neuropathy (CIPN) in patients with hematologic malignancy.We prospectively enrolled hematologic cancer patients who had a plan to receive bortezomib, thalidomide, or vincristine. Baseline NGF levels were measured within one week before the start date of chemotherapy. Follow-up NGF levels were measured after four months from the start date of chemotherapy or the date when CIPN was initially diagnosed.Baseline and follow-up NGF pairs were measured in 45 patients (male/female = 27/18, median age = 63 years old). CIPN has developed in 28 patients. In the CIPN group, the level of NGF was significantly decreased after chemotherapy compared to the baseline (?NGF = -3.52 ±5.72; p-value = 0.003), while the NGF level of the no-CIPN group was not changed after chemotherapy. The differences in ?NGF levels between the CIPN and no-CIPN group were more profound when analyzed in the subgroup of newly diagnosed multiple myeloma patients (?NGF = -4.14 ± 4.87 pg/ml for the CIPN group and +2.52 ± 8.39 pg/ml for the no-CIPN group; p-value = 0.043).This study shows that the depletion of NGF occurs during the development of CIPN, suggesting pathogenesis based on the role of NGF and therapeutic implications.

SUBMITTER: Youk J 

PROVIDER: S-EPMC5565270 | biostudies-other | 2017

REPOSITORIES: biostudies-other

altmetric image

Publications

Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies.

Youk Jeonghwan J   Kim Young-Sook YS   Lim Jung-Ah JA   Shin Dong-Yeop DY   Koh Youngil Y   Lee Soon-Tae ST   Kim Inho I  

PloS one 20170821 8


<h4>Objective</h4>To investigate whether the depletion of nerve growth factor (NGF) is associated with the development of chemotherapy-induced peripheral neuropathy (CIPN) in patients with hematologic malignancy.<h4>Methods</h4>We prospectively enrolled hematologic cancer patients who had a plan to receive bortezomib, thalidomide, or vincristine. Baseline NGF levels were measured within one week before the start date of chemotherapy. Follow-up NGF levels were measured after four months from the  ...[more]

Similar Datasets

| S-EPMC7764936 | biostudies-literature
| S-EPMC8394908 | biostudies-literature
| S-EPMC6682573 | biostudies-literature
| S-EPMC6379282 | biostudies-literature
| S-EPMC9408946 | biostudies-literature
| S-EPMC6471666 | biostudies-literature
| S-EPMC5450696 | biostudies-literature
| S-EPMC3696554 | biostudies-literature
| S-EPMC4592260 | biostudies-literature
| S-EPMC5268425 | biostudies-literature